NEW YORK (GenomeWeb News) – Foundation Medicine expects to price its initial public offering at between $14 and $16 per share, the company said in a recently amended Form S-1.

The Cambridge, Mass.-based cancer genomics firm added that it plans to offer 5 million shares, and that based on the midpoint price of $15 per share, it expects net proceeds of $66.9 million from its IPO.

Foundation plans to trade on the Nasdaq under ticker symbol "FMI."

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Researchers have treated an X-linked genetic disease affecting three babies in utero, Stat News reports.

The Associated Press reports that the US Centers for Disease Control and Prevention is beefing up sequencing as a tool to investigate foodborne illnesses.

Researchers have sequenced samples from ancient toilets to study past eating habits and health, NPR reports.

In Nature this week: ash dieback disease fungal genome, and more.

Jun
12
Sponsored by
Philips Genomics

This webinar will highlight a comprehensive end-to-end solution for precision care in oncology, comprising sample acquisition through to sequencing and analysis, treatment recommendations, and follow-through.

Jun
28
Sponsored by
PerkinElmer

This webinar will review a standardized, high-throughput, and fully automated library prep protocol for human metagenomic analysis.